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Abstract
Leishmania is a protozoan parasite causing several disease presentations collectively
known as leishmaniasis. Pathogenic species of Leishmania are divided into two subgen-
era, L. (Leishmania) and L. (Viannia). Species belonging to the Viannia subgenus have
only been reported in Central and South America. These species predominantly cause
cutaneous leishmaniasis, but in some cases, parasites can migrate to the nasopharyn-
geal area and cause a highly disfiguring mucocutaneous presentation. Despite intensive
efforts, no effective antileishmanial vaccine is available for use in humans, although a
few candidates mainly designed for L. (Leishmania) species are now in clinical trials.
After sequencing the genome of Leishmania panamensis, we noticed a high degree
of sequence divergence among several orthologous proteins from both subgenera.
Consequently, some of the previously published candidates may not work properly for
species of the Viannia subgenus. To help in vaccine design, we predicted CD4+ and
CD8+ T cell epitopes in the theoretical proteomes of four strains belonging to the Viannia
subgenus. Prediction was performed with at least two independent bioinformatics tools,
using themost frequent humanmajor histocompatibility complex (MHC) class I and class
II alleles in the affected geographic area. Although predictions resulted in millions of
peptides, relatively few of them were predicted to bind to several MHC alleles and can
therefore be considered promiscuous epitopes. Comparison of our results to previous
applications to species of the Leishmania subgenus confirmed that approximately half
of the reported candidates are not present in Viannia proteins with a threshold of 80%
sequence similarity and coverage. However, our prediction methodology was able to
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predict 70–100% of the candidates that could be found in Viannia. All the prediction
data generated in this study are publicly available in an interactive database called
VianniaTopes.
Database URL: http://bioinfo.indicasat.org.pa/vianniatopes/index.html
Introduction
Pathogenic parasites of the Leishmania genus cause several
disease presentations collectively known as leishmaniasis.
Clinical cases have been reported in 98 countries, with
more than 1 billion people living in affected areas (1).
Leishmania parasites are transmitted to humans and ani-
mals by phlebotomine sandflies. The parasite exists in two
major forms: promastigotes that develop within the insect
vector and amastigotes that reside within macrophages of
the vertebrate host. Leishmania species that are pathogenic
to human are divided into two subgenera, L. (Leishmania)
and L. (Viannia). Species belonging to the Viannia sub-
genus are distributed across Central and South America and
predominantly cause cutaneous leishmaniasis. However, in
some cases, the parasites can migrate to the nasopharyn-
geal area and cause mucocutaneous leishmaniasis (MCL),
a more severe clinical presentation that is exclusive to
this subgenus. The Viannia subgenus is broadly divided
into two major species complexes, namely the Leishmania
braziliensis species complex, which also includes Leish-
mania peruviana, and the Leishmania guyanensis species
complex, which also includes Leishmania panamensis.
Traditional strategies to reduce the impact of leish-
maniasis in affected areas have been mainly based on
pharmacological treatment and epidemiological control (2).
Pharmacological treatment has been hampered by the
toxicity of available therapeutic drugs and the increasing
problem of drug resistance in naturally occurring parasites
(3). These limitations, together with the fact that epidemio-
logical control is poor in many endemic countries, highlight
the importance of developing effective vaccines against the
parasite. Despite huge efforts, no effective antileishmanial
vaccine is available to date for human use (4, 5). Although
several vaccine candidates have shown positive results in
mice and dogs, very few have entered phase I and II clinical
trials. With several Leishmania genomes publicly available,
one of the most promising alternatives nowadays is the
identification of potential vaccine candidates at the genome-
wide level (5). This approach, colloquially known as reverse
vaccinology, requires a clear understanding of the cellular
and molecular nature of the immune response against the
parasite.
As with other intracellular parasites, immune response
to Leishmania infection is highly dependent on the cellular
component. Both CD4+ and CD8+ T cells are believed to be
critical for disease control and long-term protection (6–8).
A well-established model for Leishmania major infection
in mice suggests that a CD4+ Th1 response helps con-
trol the primary infection and confers immunity, while a
Th2 response favors disease progression (9). CD8+ T cells
appear to play a key role in the establishment of the Th1
response and in subsequent immune protection through
the production of IFN-γ, although their inherent cytotoxic
activity may also be important (10). While this model
appears to be valid for some species, significant differences
have been reported when considering other species and the
infection they cause in humans (11). For instance, it has
been shown that species of the Viannia subgenus promote
mixed Th1/Th2 hyperinflammatory responses in humans
(12, 13). Similarly, a number of studies have highlighted the
contradictory roles of CD8+ T cells in infection caused by
Viannia species. Some studies have shown that exacerbated
CD8+ activity with poorly regulated responses may be
associated with disease progression and evolution to MCL
(14), while finely regulated CD8+ responses are important
for disease control inL. braziliensis (15, 16) and for immune
protection against L. panamensis (17).
Due to the relevance of both CD4+ and CD8+ T cells
in the immune response against Leishmania, computational
prediction of potential antileishmanial vaccine candidates
has focused on the identification of T cell epitopes. Such
epitopes are peptides capable of binding to molecules of
the major histocompatibility complex (MHC), MHC class
I (MHC-I) for CD8+ T cells and MHC class II (MHC-II) in
the case of CD4+ T cells. The first attempts to apply reverse
vaccinology to pathogenic species of Leishmania focused
on prediction of binding to murine MHC alleles (18, 19).
Despite poor consensus among the programs, several of
the predicted peptides were experimentally confirmed to be
immunogenic. Furthermore, almost none of the best ranked
peptides came from proteins known to be antigenic or tested
as vaccine candidates in previous studies, thus highlighting
the potential of genome screening for the identification of
novel candidates. Improvement of bioinformatics methods
further allowed the prediction of binding to human MHC
(HLA) alleles. In order to reduce the number of proteins
to which T cell epitope prediction is applied, researchers
have typically focused on a pre-selected set of proteins,
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such as predicted membrane or surface-exposed proteins
(20, 21), previously studied antigenic proteins (22), excret-
ed/secreted proteins (23) or proteins overexpressed in the
amastigote stage (24). The outcomes of these studies have
been sets of best ranked peptides, predicted to bind to one
or more human MHC alleles, some of which have been
experimentally proven to be immunogenic in vitro or in
vivo. However, all of these studies have mainly focused on
Old World species of the L. (Leishmania) subgenus, with
almost no consideration of New World species.
We have previously reported that several orthologous
proteins from L. (Leishmania) and L. (Viannia) show high-
sequence divergence, which in some cases resulted in the
orthologs being considered different proteins (25). To the
best of our knowledge, only one study has so far conducted
T cell epitope prediction with human MHC alleles for a
species of the Viannia subgenus (26). In this study, the
authors screened the L. braziliensis theoretical proteome
for peptides able to bind to several MHC-I and MHC-II
alleles. A set of 10 undisclosed peptides were synthesized,
and half of them were further found to be immunogenic
in vitro. However, in this study, authors considered only
peptides derived from surface proteins conserved among
other L. (Leishmania) species, therefore potentially limit-
ing the discovery of Viannia-specific epitopes. Currently,
reference genomes are available for both L. braziliensis
(27) and L. panamensis (25), making it possible to apply
a reverse vaccinology strategy to identify potential vaccine
candidates specific to this subgenus. Here we explored the
proteins from four genomes of species belonging to the
Viannia subgenus, in order to predict CD4+ and CD8+
T cell epitopes. Instead of reporting a list of best-ranked
candidates, we stored all the positive predictions in a pub-
licly available database named VianniaTopes. This solution
allows researches not to restrict to a single set of pre-
selected candidates that may be easily discarded in subse-
quent experimental evaluation. Instead, the database can be
queried by using multiple criteria in order to add flexibility
to selection schemes. The database is free and does not
require the user to register in order to access it.
Materials and methods
Preparation of protein sequence data
We used the protein-coding genes annotated in the reference
genomes for L. braziliensis (strain M2904) (27) and L.
panamensis (strain PSC-1) (25), both downloaded from the
Genomes resource of the National Center for Biotechnol-
ogy Information. We also included the proteins from L.
braziliensis strain M2903 and L. panamensis strain L13,
downloaded from the TriTrypDB database (release 30) (28).
Genes with unsequenced segments (gaps) and potential
pseudogenes were subsequently discarded. OrthoMCL (29)
was used to cluster the proteins from L. braziliensis strain
M2903 and L. panamensis strains PSC-1 and L13 into the
ortholog groups predefined in OrthoMCL-DB (version 5),
which already contains the proteins from L. braziliensis
strain M2904. Proteins left ungrouped from each genome
were screened for sequence similarity and clustered into
additional, putative Viannia-specific groups.
Epitope prediction
Since T cell epitope predictions are highly dependent on
MHC alleles, we first searched the dbMHC database (30)
(currently available at ftp://ftp.ncbi.nlm.nih.gov/pub/mhc)
for the most frequentMHC-I andMHC-II alleles in the geo-
graphical region of interest. Since very few allele frequency
data were found for Central America, we selected the alleles
with the highest frequencies in both South andNorth Amer-
ica. Only those alleles supported by all the predictive pro-
grams described below were further considered (Figure S1).
The MHC-I alleles selected were HLA-A∗02:01, HLA-
A∗24:02, HLA-A∗31:01, HLA-A∗68:01, HLA-B∗15:01,
HLA-B∗39:01, HLA-B∗40:02, HLA-C∗03:03, HLA-C∗04:
01, HLA-C∗07:02 and HLA-C∗15:02. The MHC-II alleles
selected were HLA-DRB1∗08:02, HLA-DQA1∗03:01,
HLA-DQA1∗04:01, HLA-DQA1∗05:01, HLA-DQB1∗03:
01, HLA-DQB1∗03:02, HLA-DQB1∗04:02, HLA-DPA1∗
01:03 and HLA-DPB1∗04:02. Alleles from the DP and DQ
groups were used in the combinations HLA-DPA1∗01:03/
DPB1∗04:02, HLA-DQA1∗03:01/DQB1∗03:02, HLA-
DQA1∗04:01/DQB1∗04:02 andHLA-DQA1∗05:01/DQB1∗
03:01, corresponding to pairs of α and β chains, respec-
tively. Allele HLA-DRB1∗08:02 was used separately, since
α chains are not variable in the DR group.
Binding to MHC class I alleles was predicted for all the
nonameric (9-mer) peptides derived from the proteins of
interest by using two pan-specific methods, NetMHCpan
v. 3.0 (31) and NetCTLpan (32), as well as the allele-specific
Consensus method from the Immune Epitope Database
(IEDB) MHC-I binding prediction tool (33). Potential epi-
topes were selected on the basis of the percentile rank
(%Rank), with the cutoff values suggested by the authors
for each program, i.e. %Rank <2.0 for NetMHCpan and
%Rank<1.0 for both NetCTLpan and IEDB Consensus. In
the case of NetMHCpan, authors also suggest a cutoff value
of 0.5, below which peptides are predicted to be strong
binders (SBs) to the corresponding alleles, while peptides
with a %Rank equal or greater than 0.5 are considered to
be weak binders.
Binding to MHC class II alleles was predicted for all the
possible 15-mer peptides by using NetMHCIIpan v.3.1 (34)
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and the Consensus method of the IEDB MHC-II binding
prediction tool (35, 36). As with MHC-I potential epitopes,
the %Rank threshold suggested by the authors were used
for selection (%Rank <10.0 for NetMHCIIpan and IEDB
Consensus, %Rank <2.0 for NetMHCIIpan SBs).
Two major strategies were used to select the peptides
according to epitope predictions, namely, considering only
the peptides predicted by all the programs under the corre-
sponding cut-off values (the intersection set) or considering
all the peptides predicted by at least one program (the union
set). An allele coverage was computed for each peptide
under each selection scheme, calculated as the number of
alleles for which the corresponding peptide was predicted
to bind.
In order to predict peptides acting as combined MHC-I
and MHC-II binders, all the selected 15-mer peptides were
screened for overlapping 9-mer peptides previously pre-
dicted to act as MHC-I epitopes. For each 15-mer peptide
with at least one overlapping MHC-I binder, a coverage
of MHC-I alleles was computed in addition to its MHC-
II allele coverage. This MHC-I allele coverage was com-
puted as the nonredundant list of alleles to which all the
corresponding overlapping 9-mer peptides were previously
predicted to bind.
Estimation of peptide properties
Several basic properties were also precomputed for each
peptide to allow additional criteria useful for selection.
Approximation methods were used to calculate physic-
ochemical properties, such as the isoelectric point (pI)
and charge at neutral pH (37), as well as solubility and
hydrophobicity scores (38). Suitability of peptides for
conventional synthesis was estimated empirically by taking
into account several situations that are known to interfere
with synthesis protocols, such as the presence of N-terminal
glutamine or asparagine residues, three or more cysteine
or methionine residues, two or more aspartate residues
adjacent to glycine, proline or serine, as well as more
than 80% of the sequence composed of β-sheet forming
amino acids. Synthesis was considered to be potentially
problematic for a peptide if its sequence meets two or more
of the previous criteria.
Sequence similarity searches and conservation
analysis
BLAST (Basic Local Alignment Search Tool) (39) was used
to align all the peptides to the proteins encoded in the
human, mouse and L. major reference genomes. Several
default options were adjusted to increase the sensitivity
of BLAST searches performed with short input sequences.
These include decreasing the word size to 2, increasing
the expected value threshold to 20 000, using the PAM30
scoringmatrix and deactivating compositional adjustments.
Presence of the peptides in the theoretical proteome of
the subject species was reported if query coverage and
percent identity were both above 80%. The same strategy
for alignment and selection thresholds were used when
comparing our predicted peptides to those stored in the
IEDB database.
Database and web interface implementation
The VianniaTopes database was implemented in MySQL
(MariaDB server v. 5.5) running on an Apache HTTP server
in a 64-bit Linux system (Centos 7). MHC-I and MHC-II
binding predictions for each peptide/allele pair were stored
separately in the database and linked to the corresponding
allele, peptide and protein tables by using a relational
scheme (see Results). The web interface was designed by
using conventional HTML and CSS styling, with the Perl
5 DBI and CGI modules for database interaction and web
execution, respectively.
Results
Protein selection
A total of 33 870 proteins from the genomes of four
strains belonging to the Viannia subgenus were selected
for epitope prediction in this study. The selected proteins
were clustered into 7624 ortholog groups, of which, 95
did not have representatives in other L. (Leishmania)
species and are therefore potentially exclusive to the
Viannia subgenus (Table S1). These groups were later
used to select putative Viannia-specific epitopes (see
Peptide properties and conservation analysis). Several pro-
teins encoded by the genes in these groups are widely
known to be critical for Leishmania virulence, and some
of them are highly immunogenic. These include proteins
involved in the synthesis of surface components such as the
proteophosphoglycan, secreted proteases and membrane
transporters.
Prediction of T cell epitopes
Epitope predictions were performed individually for each
protein, using at least two predictive programs per MHC
class. Since species of the Viannia subgenus have been
exclusively reported in Central and South America, we
intended to select the most frequent MHC alleles in both
regions. However, due to the general lack of information
regarding MHC allele frequencies in Central America, we
selected those alleles that have a relatively high frequency
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Figure 1. General statistics of T cell epitope predictions summarized by allele and predictive program for MHC-I (A) and MHC-II (B) alleles. Bars
indicate the number of predictions per program expressed as peptide/allele pairs. Lines indicate the total number of predictions per allele, taking
into account all the predictions from NetMHCpan/NetMHCIIpan or only the SB.
and are present in both North and South America in the
dbMHC database. In order to report comparable results,
we further considered those alleles supported by all the pre-
dictive programs used for each MHC class, thus reducing
the number of tested alleles to 11 MHC-I alleles and five
combinations of nine MHC-II alleles (Figure S1).
Predictions were selected according to %Rank instead
of binding affinity, since estimates of binding affinity are
considered less reliable and are allele-dependent (40). Selec-
tion was done according to the%Rank cutoff values recom-
mended by the authors, which for MHC-I prediction tools
are between 1.0 and 2.0%. In order to cover all possible
scenarios, we used two independent methods for clustering
predictions, namely considering those peptide/allele pairs
predicted by all the programs (the intersection set) or by at
least one program (the union set). For MHC-I predictions,
the union set has over 2.8 million peptide/allele pairs,
while the intersection set includes 472 766 of these pairs
(Figure S2). These numbers were respectively reduced to
802 545 and 196 892 when considering only the pairs with
a NetMHCpan %Rank <0.5, colloquially known as SBs.
The total number of predictions per allele varied greatly
among programs (Figure 1). The major source of this varia-
tion appears to be the number of NetMHCpan predictions,
which was always higher than those from NetCTLpan
and IEDB Consensus. However, the number of predictions
appears to be roughly similar among the three programs
when considering only the SB. It is also important to
mention that the number of NetMHCpan predictions for
HLA-C alleles was relatively higher than those observed for
the rest of the alleles, although the difference is also less
noticeable when considering only the SB.
The number of MHC-II binding predictions was always
notably higher than the corresponding MHC-I predictions
in each set, with nearly 6 million peptide/allele pairs in
the union set and over 2.5 million in the intersection set
(Figure S2). Since binding prediction is less reliable for
MHC-II than for MHC-I, cutoff values recommended for
%Rank are larger than those used for MHC-I, i.e. 10.0%
for both NetMHCIIpan and IEDB Consensus and 2.0%
for NetMHCIIpan SB. As expected, the number of SB was
notably lower than the total number of binders predicted
by NetMHCIIpan, but in this case, the number of IEDB
Consensus predictions per alleles appears to be globally
more similar to the latter (Figure 1B). Despite the lower
number of alleles considered, we also observed variations in
the number of predictions per allele, particularly for alleles
HLA-DQA1∗05:01/DQB1∗03:01 and HLA-DRB1∗08:02.
Since predictions were made by testing a peptide against
several alleles, the same peptide can, and usually have, more
than one positive prediction in the results, each one for a dif-
ferent allele. In order to group the results by peptide, instead
of peptide/allele pairs, we counted the alleles to which each
peptide was predicted to bind under each selection method
(union or intersection). This measure was termed allele
coverage and was considered to be a general indicator of
how promiscuous peptides are in their capacity to bind
to MHC alleles. Table 1 shows the nonredundant number
of peptides computed for each category after summarizing
across alleles.
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Table 1. Nonredundant number of predicted peptides
Selection method MHC-I MHC-II
Union 1 437 008 3 516 121
Union (SB) 605 470 2 317 664
Intersection 218 376 1 702 834
Intersection (SB) 182 806 645 941
As expected, the nonredundant number of peptides in
each category is always lower than the corresponding num-
ber of predictions, but the number of MHC-II binding
peptides is also higher than that ofMHC-I binding peptides.
Regardless of the selection method, the number of peptides
dramatically decreases with the increase in allele coverage
(Figure 2). For MHC-I predictions, no peptide was found
to have a 100% allele coverage either in the intersec-
tion or the union set. In the case of MHC-II predictions,
only four peptides were concurrently predicted to cover
all alleles (AAWAFVAALSRLLVC, ERFFSFMAAARARLE,
SVAAWAFVAALSRLL and VAAWAFVAALSRLLV).
Additionally, 15-mer peptides were screened for overlap-
ping 9-mers previously predicted to act as MHC-I epitopes,
in order to identify peptides potentially capable to activate
both CD4+ and CD8+ T cells. When using the union as the
selection method, 3 052 839 15-mer peptides (87%) were
found to have at least one overlapping MHC-I binding pep-
tide. This number is reduced to 1 783 083 when considering
only NetMHCpan and NetMHCIIpan SB. When using the
intersection as selection method, the numbers are reduced
to 924 085 and 809 810 for all the predictions or only the
SB, respectively.
Peptide properties and conservation analysis
Since the main goal of this work was the development of a
database of predicted immunogenic peptides, we estimated
several properties in addition to epitope predictions,
which can help narrow the results of further selection
strategies. These properties include molecular weight, pI,
net charge, water solubility at neutral pH and suitability for
conventional synthesis. It is important to mention that 30%
of the peptides were predicted to have poor water solubility
at neutral pH, a property that should be considered critical
when selecting peptides to be synthesized for subsequent
in vitro and in vivo assays. These estimations allow
researchers to find a workaround to the experimental use of
these peptides, such as changing the pH or coupling them
to protein carriers.
To account for important taxonomic constraints in selec-
tion strategies, we also aligned all the predicted peptides to
the mouse, human and L. major theoretical proteomes. A
total of 81 515 (2%) and 71 683 (1%) peptides were found
to share sequence similarity with human and mouse pro-
teins, respectively, with query coverage and identity above
80%. On the contrary, 47% of all the predicted peptides
exhibited sequence similarity with L. major proteins when
using the previously mentioned thresholds. However, only
14% of the peptides were found to be present in L. major
proteins with identical sequence.Nearly 6000 peptides with
low-sequence similarity (<40%) to L.major proteins derive
from potentially Viannia-specific ortholog groups reported
in Table S1. Of these peptides, 44 were predicted to bind to
more than one MHC-II allele and have at least one over-
lapping MHC-I peptide with comparable allele coverage
(Table S2). These peptides can be considered as potentially
promiscuous Viannia-specific epitopes.
Database implementation
The VianniaTopes database was implemented by using a
relational model, normalized to the third normal form
(Figure 3). In the VianniaTopes model, MHC binding
Figure 2. Number of peptides per allele coverage for selected MHC-I (A) and MHC-II (B) alleles. Plots show the nonredundant number of peptides
predicted to bind two one or more alleles under each selection method. The same scale is used in both plots to emphasize the differences between
both classes.
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Figure 3. The entity-relationship diagram for the VianniaTopes database. Relationship among tables is represented by connecting lines, fields acting
as primary keys are highlighted in bold and foreign keys are highlighted in italics.
predictions in the form of peptide/allele pairs were stored in
separate tables and further linked to nonredundant tables
of alleles and peptides. Peptide tables (MHCI peptides
and MHCII peptides) store allele coverage values for
each peptide under each selection scheme, as well as
their taxonomic conservation and estimated values for
physicochemical properties. These tables are also connected
to an independent table (Peptides per protein) that indexes
all the occurrences of each peptide in the sequences of the
original proteins, which are in turn stored in the Proteins
table. Consequently, this index table associates the peptide-
based predictions with the proteins where the peptides
appear. This association allows one to incorporate protein-
related information in queries based on peptide properties,
such as the presence of such peptides in proteins from
ortholog groups conserved across the Leishmania genus
or those sharing human or mouse orthologs.
The web interface allows users to separately search for
peptides predicted to bind to MHC-I or MHC-II alleles,
as well as the combined predictions. The database can
be queried by peptide properties or by peptide sequence
(Figure 4A). Queries based on peptide properties can be
performed under one of the two proposed selection schemes
(union or intersection) and can be constrained by several
criteria, including allele coverage, peptide properties and
taxonomic grouping. In all cases, the output of each search
is interactive and can be sorted by different criteria or
exported to text files with tab-separated values (Figure 4B).
Validation
In order to validate our prediction methodology, we
intended to compare our results with those of previous
applications of reverse vaccinology to the Leishmania
genus. However, this comparison was hampered by the fact
that most of these studies focused on species belonging to
the L. (Leishmania) subgenus, such as L.major,Leishmania
infantum and Leishmania donovani. Consequently, many
of the predicted peptides are not present with identical
sequence in orthologous proteins from the Viannia
subgenus due to sequence divergence. For instance, of the
34 peptides derived from the L.major theoretical proteome,
suggested by Singh et al. (21) as optimal epitopes for the
South American population, only five were found to be sim-
ilar to proteins from species of the Viannia subgenus under
the 80% threshold of query coverage and sequence identity.
However, these five peptides were indeed selected by our
methodology with comparable allele coverage (Table S3).
Consequently, we first selected the peptides reported by
four comprehensive studies that performed experimental
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Figure 4. The VianniaTopes web interface. (A) Main search options for MHC-I prediction data. (B) Sample result for a search by peptide properties
using the criteria shown in panel A.
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Table 2.Comparison of results from this studywith those of previous applications of reverse vaccinology to pathogenic species
of Leishmania
Seyed et al. (22) Agallou et al. (41) Naouar et al. (23) Dikhit et al. (24)
Total peptides 18 145 78 37
Present in Viannia 9 (50%)a 58 (40%) 35 (45%) 8 (22%)
Present in VianniaTopes 9 (100%)b 43 (74%) 24 (69%) 8 (100%)
Not found in Viannia 9 (50%)a 87 (60%) 43 (55%) 29 (78%)
aPercentages referred to the total number of peptides.
bPercentages referred to the number of peptides found in Viannia proteins.
validation of their results (Table 2). We then checked if
those peptides that are present in the theoretical proteomes
of Viannia species, with the previously mentioned sim-
ilarity thresholds, were predicted by our methodology
and are therefore present in the VianniaTopes database
(Table S3).
Seyed et al. (22) reported 18 peptides derived from
six previously known L. major antigenic proteins. These
peptides were then evaluated for binding to the HLA-A2
alleles most frequent in SouthWest Asian populations.Nine
of these peptides could be found in the Viannia theoretical
proteomes and were also predicted by our methodology.
Naouar et al. (23) reported 78 peptides derived from L.
major excreted/secreted proteins as potential binders to
allele HLA-A∗02:01. Only 35 of these peptides could be
found in Viannia proteins, and 24 of them were also pre-
dicted by our methodology as candidate binders to HLA-
A∗02:01. Dikhit et al. (24) suggested 37 peptides capable
of binding to several MHC-II alleles, derived from proteins
overexpressed in L. donovani amastigotes. Only eight of
these peptides were found to be present in Viannia proteins,
and all of them were predicted by our methodology as well.
Agallou et al. (41) first screened proteins from L. major
using murine MHC alleles. However, binding to human
MHC-I andMHC-II alleles was predicted only for synthetic
multi-epitope peptides designed later. Of the 145 initially
reported peptides, only 58 were found in Viannia proteins,
and 43 of these were predicted by our methodology.
Although these four studies performed experimental
immunogenicity evaluation of the reported peptides, direct
comparison with our results was not always possible, since
the experimental assays were not necessarily performed
for individual peptides. For instance, Seyed et al. (22)
performed the experimental assays in pools of peptides,
while Agallou et al. (41) used synthetic multi-epitope
peptides. However, of the six peptides evaluated in vitro by
Dikhit et al. (24), only peptide FDLFLFSNGAVVWWGwas
found to be present in Viannia, and it was also predicted
by our methodology. Similarly, from the six peptides
found to be immunogenic in vitro by Naouar et al. (23),
peptides YLRTFPAAL and TLGVKQMVV were found in
Viannia, although only the former was predicted by our
methodology.
For a more comprehensive analysis, we compared
our predicted peptides with those reported in studies
conducted with Leishmania species in the IEDB database.
This database stores results from only two studies that
exclusively performed experimental assays with peptides
derived from species of the Viannia subgenus, one in L.
braziliensis (42) and the other one in L. panamensis (43).
These studies collectively reported 14 peptides as potential
T cell epitopes, all of which have associated prediction data
in VianniaTopes (Table S4). However, there are more than
900 epitopes derived from other species of Leishmania in
this database,many of which share sequence similarity with
Viannia proteins under the previously mentioned similarity
thresholds. Using these thresholds, we found that 2356
(MHC-I) and 2696 (MHC-II) peptides from VianniaTopes
have associated experimental data on IEDB. Of which,
804 (MHC-I) and 757 (MHC-II) have positive results in T
cell or MHC binding assays. The presence of experimental
evidence in the IEDB database was incorporated into the
corresponding peptide tables of VianniaTopes and was also
included as a selection criterion on the web interface, for
both MHC-I and MHC-II epitopes.
Discussion
During the last decade, there have been several examples of
application of reverse vaccinology to the pathogenic species
of Leishmania. Most of these studies considered Old World
species belonging to the L. (Leishmania) subgenus,with few
applications to New World species and those belonging to
the L. (Viannia) subgenus. Orthologous proteins from both
subgenera may differ largely due to sequence divergence.
This situation may cause that effective candidates designed
for species belonging to the L. (Leishmania) subgenus could
fail to induce a protective response against species from
the Viannia subgenus, especially if they derive from highly
divergent proteins. Also, the majority of the previous works
has also focused in a limited set of proteins for epitope
prediction, selected on the basis of previously reported
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immunogenicity, subcellular localization or overexpression
in the amastigote stage. One of the very few studies that
have included a species from the Viannia subgenus, L.
braziliensis, narrowed the predictions to proteins shared
with L. (Leishmania) species, thus potentially missing Vian-
nia-specific candidates. Unfortunately, authors of this study
did not publicly disclose the sequences of the selected
peptides.
The main goal of this work was to identify potential
CD4+ and CD8+ T cell epitopes by screening four genomes
publicly available for species of the Viannia subgenus. The
selected genomes cover two representative species from
each of the two recognized species complexes of theViannia
subgenus, namely, L. braziliensis and L. panamensis. In
order to avoid missing potentially good candidates, we did
not discard candidates on the basis of properties and taxo-
nomic distribution of the proteins from which they derive.
Instead, all predictions meeting the selected cutoff values
were stored in a publicly accessible database called Vian-
niaTopes, intended to aid research groups working with
the corresponding species. After several applications of the
reverse vaccinology strategy to this and other pathogenic
species, we have noticed that authors end up with relatively
few candidates, whose number is reduced even more after
performing experimental evaluation. In addition, candi-
dates are sometimes filtered by properties that may not be
as relevant as expected for protective immune responses
against the corresponding pathogens, such as the use of B
cell epitopes and the prioritization of surface-exposed or
overexpressed proteins in Leishmania vaccine design (19).
Availability of a database of unfiltered precomputed pep-
tide/allele predictions allows researchers to choose among
several properties of the peptides and their source proteins,
in order to add flexibility to selection schemes customized
according to their interests and priorities. This resource,
however, does not pretend to compete with other compre-
hensive databases of experimentally characterized epitopes,
such as IEDB. Instead, it is considered as a tool offering
precomputed predictions made with a subset of alleles
relevant to the geographic area that is affected by these
particular parasites.
Predictions were performed by at least two indepen-
dent programs per MHC class. MHC-I binding predictions
were performed by using NetMHCpan, NetCTLpan and
IEDBConsensus,whileMHC-II predictions were done with
NetMHCIIpan and IEDB Consensus. It is important to
mention that NetCTLpan relies on an earlier version of
NetMHCpan (v. 2.3), but also uses complementary pre-
dictions of proteasomal cleavage and efficiency of antigen
transport, two critical steps in the MHC-I presentation
pathway. The Consensus tool from IEDB, in turn, combines
the results of several predictive methods for MHC-I and
MHC-II binding, based on artificial neural networks, stabi-
lized matrix methods and other machine learning strategies.
We observed several differences in the results, not only
regarding individual peptide predictions, but also in the
global number of predictions per allele. However, a rel-
atively large degree of consensus among the programs
allowed us to cluster the predictions in an intersection
set, which includes peptides concurrently predicted by all
programs in each class. To account for predictions for
which there was partial or no consensus, we also com-
puted a union set. Furthermore, suggested NetMHCpan
and NetMHCIIpan cut-off values were used to classify the
predicted peptides as strong and weak binders. In the case
of MHC-I binding predictions, the number of SB is roughly
similar to the number of binders predicted by the other two
programs. Data from all the clustering sets were stored in
the database and can be accessed by properly setting the
search parameters in the user interface. In addition to the
epitope prediction metrics such as rank and binding affinity,
a relevant criterion for peptide selection in the database
is allele coverage. This value is defined as the number of
alleles to which a peptide was predicted to bind under each
clustering set. Peptides capable of binding to several alleles,
colloquially known as promiscuous, are expected to cover
a larger portion of the target population and are therefore
better candidates for a protective vaccine. As expected, the
number of peptides markedly decreases as allele coverage
increases, for both MHC-I and MHC-II alleles.
Although the primary goal of this work was to cre-
ate a comprehensive database instead of suggesting a list
of best-ranked candidates, we explored the number of
peptides predicted to be promiscuous in proteins from
ortholog groups that are potentially specific to the Viannia
subgenus. We found 44 peptides deriving from such pro-
teins that are capable of binding to more than one MHC-II
alleles, with a similar coverage of MHC-I alleles when con-
sidering their overlapping 9-mers.Most of these potentially
promiscuous peptides come from proteins whose func-
tion is still unknown, except for a phosphoglycan β-1,3-
galactosyltransferase (LbrM.02.0240/LpmP.02.0140) and
a glutathione peroxidase (LbrM.26.0810/LpmP.26.0780).
Proteins with both of these functions are well-known vir-
ulence determinants in Leishmania. Curiously, LbrM.26.
0810/LpmP.26.0780 has been recently identified as an addi-
tional gene encoding glutathione peroxidase in the genomes
of Viannia species (25). As a potentially specific feature
of the Viannia subgenus, this gene was implicated in the
development of MCL and perhaps other atypical disease
presentations.
Together with peptides coming from genes that are
potentially Viannia-specific, we found over 6000 peptides
with low similarity to L. major proteins. This finding
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evidences the high sequence divergence that exists in some
orthologous proteins shared by the L. (Leishmania) and
L. (Viannia) subgenera, despite a global conservation in
gene content and order on their genomes. Due to this varia-
tion, we were not entirely able to compare our results with
previous studies applying reverse vaccinology to pathogenic
Leishmania species, all of which have mainly focused on
the L. (Leishmania) subgenus. However, 70–100% of the
peptides that could be found in Viannia were predicted by
our methodology with similar metrics and allele coverage.
The VianniaTopes database can be very helpful to research
groups working with pathogenic Viannia species, which
affect several countries of Central and South America.
Peptides suspected to be Viannia-specific promiscuous
epitopes can be evaluated as independent candidates or as
members of multi-epitope constructions targeting a broader
group of species or a larger geographic region.
Supplementary data
Supplementary data are available at Database Online.
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